CR11579A - Derivados de oxadiazol activos sobre fosfato de esfingosina-1 - Google Patents

Derivados de oxadiazol activos sobre fosfato de esfingosina-1

Info

Publication number
CR11579A
CR11579A CR11579A CR11579A CR11579A CR 11579 A CR11579 A CR 11579A CR 11579 A CR11579 A CR 11579A CR 11579 A CR11579 A CR 11579A CR 11579 A CR11579 A CR 11579A
Authority
CR
Costa Rica
Prior art keywords
active
sphingosine
phosphate
oxadiazol derivatives
oxadiazol
Prior art date
Application number
CR11579A
Other languages
English (en)
Inventor
Emmanuel Hubert Demont
Jag Paul Heer
Thomas Daniel Heightman
David Nigel Hurst
Christopher Norbert Johnson
John Skidmore
Ian David Wall
Jason Witherington
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0725120A external-priority patent/GB0725120D0/en
Priority claimed from GB0821918A external-priority patent/GB0821918D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CR11579A publication Critical patent/CR11579A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La presente solicitud describe compuestos a base de oxadiazol de la formula (I), activos sobre 1-fosfato esfingosina (S1P) en particular utiles para tratar lupus eritematoso; A es fenilo o un anillo de heteroarilo de 5 o 6 miembros; R1 es de hasta dos sustituyentes independientemente seleccionados de halogeno
CR11579A 2007-12-21 2010-07-21 Derivados de oxadiazol activos sobre fosfato de esfingosina-1 CR11579A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0725120A GB0725120D0 (en) 2007-12-21 2007-12-21 Compounds
GB0821918A GB0821918D0 (en) 2008-12-01 2008-12-01 Compounds

Publications (1)

Publication Number Publication Date
CR11579A true CR11579A (es) 2010-09-03

Family

ID=40342566

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11579A CR11579A (es) 2007-12-21 2010-07-21 Derivados de oxadiazol activos sobre fosfato de esfingosina-1

Country Status (28)

Country Link
US (2) US8222245B2 (es)
EP (1) EP2222669B1 (es)
JP (1) JP2011506569A (es)
KR (1) KR20100108566A (es)
CN (1) CN101945863B (es)
AR (1) AR069916A1 (es)
AU (1) AU2008339988B2 (es)
BR (1) BRPI0820131A2 (es)
CA (1) CA2710130A1 (es)
CO (1) CO6290646A2 (es)
CR (1) CR11579A (es)
DK (1) DK2222669T3 (es)
DO (1) DOP2010000194A (es)
EA (1) EA017691B1 (es)
ES (1) ES2434730T3 (es)
HR (1) HRP20130957T1 (es)
IL (1) IL206235A0 (es)
MA (1) MA31924B1 (es)
NZ (1) NZ585996A (es)
PE (1) PE20091339A1 (es)
PL (1) PL2222669T3 (es)
PT (1) PT2222669E (es)
RS (1) RS53038B (es)
SI (1) SI2222669T1 (es)
TW (1) TWI415847B (es)
UY (1) UY31570A1 (es)
WO (1) WO2009080725A1 (es)
ZA (1) ZA201003963B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007026341A1 (de) 2007-06-06 2008-12-11 Merck Patent Gmbh Benzoxazolonderivate
DE102007032507A1 (de) 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
TWI431010B (zh) 2007-12-19 2014-03-21 Lilly Co Eli 礦皮質素受體拮抗劑及使用方法
GB0725102D0 (en) * 2007-12-21 2008-01-30 Glaxo Group Ltd Compounds
GB0725105D0 (en) 2007-12-21 2008-01-30 Glaxo Group Ltd Compounds
GB0725101D0 (en) 2007-12-21 2008-01-30 Glaxo Group Ltd Compounds
DE102007061963A1 (de) 2007-12-21 2009-06-25 Merck Patent Gmbh Pyridazinonderivate
DE102008019907A1 (de) 2008-04-21 2009-10-22 Merck Patent Gmbh Pyridazinonderivate
GB0807910D0 (en) 2008-04-30 2008-06-04 Glaxo Group Ltd Compounds
DE102008028905A1 (de) 2008-06-18 2009-12-24 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
US8586599B2 (en) 2008-12-22 2013-11-19 Merck Patent Gmbh Polymorphic forms of 6-(1-methyl-1H-pyrazol-4-yl)-2-{3-[5-(2-morpholin-4-yl-ethoxy)-pyrimidin-2-yl]-benzyl}-2H-pyridazin-3-one dihydrogenphosphate and processes of manufacturing thereof
GB0910674D0 (en) 2009-06-19 2009-08-05 Glaxo Group Ltd Novel compounds
WO2011028927A1 (en) * 2009-09-04 2011-03-10 Allergan, Inc. Selective sphingosine-1-phosphate receptor antagonists
ES2648820T3 (es) 2011-05-10 2018-01-08 Gilead Sciences, Inc. Compuestos heterocíclicos condensados como moduladores de los canales de sodio
CN102250035A (zh) * 2011-06-10 2011-11-23 北京富卡生物技术有限公司 二芳基取代-1，3，4-噁二唑化合物的合成方法和其药物用途
TWI478908B (zh) 2011-07-01 2015-04-01 Gilead Sciences Inc 作為離子通道調節劑之稠合雜環化合物
NO3175985T3 (es) 2011-07-01 2018-04-28
RU2543485C2 (ru) * 2013-02-26 2015-03-10 Андрей Александрович Иващенко Гетероциклические агонисты рецепторов желчных кислот tgr5, фармацевтическая композиция, способы их получения и применения
CN104844535A (zh) * 2014-02-13 2015-08-19 吉利德科学公司 用于制备稠合杂环离子通道调节剂的方法
TWI689487B (zh) 2014-08-20 2020-04-01 美商必治妥美雅史谷比公司 經取代雙環化合物
EP3218371B1 (en) * 2014-11-14 2018-09-26 Boehringer Ingelheim International GmbH Aryl and heteroaryl-fused tetrahydro-1,4-oxazepine amides as somatostatin receptor subtype 4 (sstr4) agonists
WO2016087370A1 (en) * 2014-12-01 2016-06-09 Actelion Pharmaceuticals Ltd Cxcr7 receptor modulators
IL271149B2 (en) * 2017-06-14 2024-05-01 Trevena Inc Compounds for modulating s1p1 activity and methods of using the same
WO2022173795A1 (en) * 2021-02-10 2022-08-18 Icahn School Of Medicine At Mount Sinai OXADIAZOLYL DIHYDROPYRANO[2,3-b]PYRIDINE INHIBITORS OF HIPK2 FOR TREATING KIDNEY FIBROSIS
EP4426285A4 (en) * 2021-11-04 2025-10-22 Valo Health Inc HISTONE DEACETYLASE 6 INHIBITOR COMPOUNDS AND USES THEREOF

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3964478B2 (ja) 1995-06-30 2007-08-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬
JPH1180026A (ja) 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
US7429579B2 (en) 2000-11-14 2008-09-30 Smithkline Beecham, Plc Tetrahydrobenzazepine derivatives useful as modulators of dopamine D3 receptors (antipsychotic agents)
EP1549640A4 (en) 2002-06-17 2008-08-06 Merck & Co Inc 1 - ((5-ARYL-1,2,4-OXADIAZOL-3-YL) BENZYL) AZETIDINE-3-CARBOXYLATE AND 1 - ((5-ARYL-1,2,4-OXADIAZOL-3-YL) BENZYL) PYRROLIDIN-3-CARBOXYLATE AS EDG RECEPTOR AGONISTS
BRPI0410746A (pt) 2003-05-19 2006-06-27 Irm Llc compostos e composições imunossupressoras
AU2004277947A1 (en) * 2003-10-01 2005-04-14 Merck & Co., Inc. 3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as S1P receptor agonists
CN1894225A (zh) 2003-12-17 2007-01-10 默克公司 作为鞘氨醇1－磷酸(内皮分化基因)受体激动剂的(3,4－二取代)丙酸酯
EP1760071A4 (en) 2004-06-23 2008-03-05 Ono Pharmaceutical Co COMPOUND WITH S1P RECEPTOR BINDING ABILITY AND USE THEREOF
GB0414795D0 (en) 2004-07-01 2004-08-04 Glaxo Group Ltd Compounds
WO2006047195A2 (en) 2004-10-22 2006-05-04 Merck & Co., Inc. 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as s1p receptor agonists
EP2371811B1 (en) 2004-12-13 2014-10-08 Ono Pharmaceutical Co., Ltd. Azetidinecarboxylic acid derivative and medicinal use thereof
WO2006100631A1 (en) * 2005-03-23 2006-09-28 Actelion Pharmaceuticals Ltd Hydrogenated benzo (c) thiophene derivatives as immunomodulators
DE602006003642D1 (en) 2005-03-23 2008-12-24 Actelion Pharmaceuticals Ltd Neue thiophen-derivate als sphingosin-1-phosphat-1-rezeptorantagonisten
EP1873153B1 (en) 2005-04-22 2010-07-07 Daiichi Sankyo Company, Limited 3-azetidinecarboxylic acid derivatives for use as immunosuppressants
EP1893591A1 (en) * 2005-06-08 2008-03-05 Novartis AG POLYCYCLIC OXADIAZOLES OR I SOXAZOLES AND THEIR USE AS SlP RECEPTOR LIGANDS
CA2619101A1 (en) 2005-08-23 2007-03-01 Irm Llc Immunosuppressant compounds and compositions
JP2009517351A (ja) 2005-11-24 2009-04-30 グラクソ グループ リミテッド 化学物質
TWI382984B (zh) 2006-04-03 2013-01-21 Astellas Pharma Inc 雜環化合物
WO2008064337A2 (en) 2006-11-21 2008-05-29 University Of Virginia Patent Foundation Benzocycloheptyl analogs having sphingosine 1-phosphate receptor activity
GB0725101D0 (en) 2007-12-21 2008-01-30 Glaxo Group Ltd Compounds
GB0725104D0 (en) 2007-12-21 2008-01-30 Glaxo Group Ltd Compounds
GB0725105D0 (en) 2007-12-21 2008-01-30 Glaxo Group Ltd Compounds
GB0725102D0 (en) 2007-12-21 2008-01-30 Glaxo Group Ltd Compounds

Also Published As

Publication number Publication date
US20100174065A1 (en) 2010-07-08
TWI415847B (zh) 2013-11-21
AU2008339988A1 (en) 2009-07-02
US20100273771A1 (en) 2010-10-28
DOP2010000194A (es) 2010-08-15
ES2434730T3 (es) 2013-12-17
MA31924B1 (fr) 2010-12-01
NZ585996A (en) 2012-06-29
JP2011506569A (ja) 2011-03-03
KR20100108566A (ko) 2010-10-07
CN101945863A (zh) 2011-01-12
HK1142062A1 (en) 2010-11-26
IL206235A0 (en) 2010-12-30
PT2222669E (pt) 2013-10-28
AU2008339988B2 (en) 2013-09-26
EA201070782A1 (ru) 2010-12-30
CA2710130A1 (en) 2009-07-02
EP2222669A1 (en) 2010-09-01
EA017691B1 (ru) 2013-02-28
PE20091339A1 (es) 2009-09-26
CN101945863B (zh) 2013-07-03
SI2222669T1 (sl) 2013-10-30
RS53038B (sr) 2014-04-30
PL2222669T3 (pl) 2014-01-31
BRPI0820131A2 (pt) 2015-05-12
EP2222669B1 (en) 2013-08-21
WO2009080725A1 (en) 2009-07-02
TW200940531A (en) 2009-10-01
ZA201003963B (en) 2011-11-30
DK2222669T3 (da) 2013-10-28
US8222245B2 (en) 2012-07-17
AR069916A1 (es) 2010-03-03
CO6290646A2 (es) 2011-06-20
UY31570A1 (es) 2009-05-29
HRP20130957T1 (hr) 2013-11-08

Similar Documents

Publication Publication Date Title
CR11579A (es) Derivados de oxadiazol activos sobre fosfato de esfingosina-1
EA201170096A1 (ru) Замещенные производные пиримидона
AR078163A1 (es) Utilizacion de aminodihidrotiazinas para el tratamiento o prevencion de la diabetes
PE20091068A1 (es) Compuestos pirrolo[3,2-d]pirimidina y su uso como inhibidores de quinasa pi3 y quinasa mtor
CO6290688A2 (es) Derivados de oxadiazol activos en 1-fosfato de esfingosina
EA201101089A1 (ru) Производные оксадиазола в качестве агонистов рецептора s1p1
NO20070731L (no) Heterocykliske forbindelser.
BR112013000273A2 (pt) derivados de imidazopiridina, processo para a preparação dos mesmos e uso terapêutico dos mesmos
EA201000947A1 (ru) Производные тиазола, применимые в качестве ингибиторов киназы pi3
PE20190336A1 (es) Nuevos derivados de amonio, un proceso para su preparacion y composiciones farmaceuticas que los contienen
AR065337A1 (es) Proceso para la sintesis de compuestos de 2- aminotiazol como inhibidores de quinasa, forma polimorfica
UY31254A1 (es) Derivados sutituidos de n4-(5-metil-1h-pirazol-3-il)- 1,3,5-triazina-2,4-diamina, sus enantiómeros, sales farmacéuticamente aceptables de los mismos, composiciones, procesos de preparación y aplicaciones
UY30323A1 (es) Uso de bifenilamidas de acido arilcarboxilico para el tratamiento de semillas
WO2008116064A3 (en) Fused heterocyclic compounds useful for the treatment of proliferative, allergic, autoimmune or inflammatory diseases
CA2671233A1 (en) Soil treating agent or seed treating agent comprising quinoline compounds or salts thereof as active ingredient, or method for preventing plant diseases by using the same
BR112012001031A8 (pt) Compostos espiro amino adequados para o tratamento de inter alia distúrbios do sono e toxicodependência
AR080596A1 (es) Compuestos alquilamido y composiciones farmaceuticas
MA32192B1 (fr) Composés dérivés d'azétidines, leur préparation et leur application en thérapeutique
PH12015501098A1 (en) Antituberculous composition comprising oxazole compounds
MY153042A (en) Novel (6-oxo-1, 6-dihydro-pyrimidin-2-yl)-amide derivatives, preparation thereof, and pharmaceutical use thereof as akt(pkb) phosphorylation inhibitors
CO6241117A2 (es) Derivados de n-(fenil) -n-morfolin-4-il-piridin -2-il) - -pirimidina-2, 4-diamina como inhibidores del ephb4 quinasa para el tratamiento de condiciones proliferativas
BR112014031969A2 (pt) derivados de pirimidinona como agentes antimaláricos
AR069781A1 (es) Compuestos de n-(2,3-dihidro-inden-2-il) propanosulfonamida, composicion farmaceutica que los comprenden y su uso para el tratamiento de la ezquizofrenia.
CY1113251T1 (el) Παραγωγα σουλφονυλ-κινολινης
MX2016001391A (es) Compuestos de urea y su uso como inhibidores de la enzima amida hidrolasa de acido graso (faah).

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)